Target Name: RNF146
NCBI ID: G81847
Review Report on RNF146 Target / Biomarker Content of Review Report on RNF146 Target / Biomarker
RNF146
Other Name(s): Iduna | RP3-351K20.1 | Ring finger protein 146 (Dactylidin) | E3 ubiquitin-protein ligase RNF146 (isoform a) | E3 ubiquitin-protein ligase RNF146 | Ring finger protein 146, transcript variant 2 | RN146_HUMAN | dJ351K20.1 | Dactylidin | RNF146 variant 2 | 2610509H23Rik | RING finger protein 146 | dactylidin | iduna | RNF146 variant 1 | ring finger protein 146 | RING-type E3 ubiquitin transferase RNF146 | Ring finger protein 146, transcript variant 1

Unlocking the Potential of RNF146 (Iduna) as a Drug Target and Biomarker

Abstract:

RNF146 (Iduna) is a non-coding RNA molecule that has been identified as a potential drug target and biomarker. Its unique structure and biochemical properties make it an attractive target for drug development. This article will discuss the potential of RNF146 (Iduna) as a drug target and biomarker, highlighting its unique features, current research progress, and potential future in drug development.

1. Introduction

Rheumatoid arthritis (RA) is a chronic autoimmune disorder that affects millions of people worldwide. The immune system attacks the joints, leading to inflammation, pain, and joint damage. While several treatments have been developed to manage RA, the disease remains a significant public health issue. Therefore, there is a need for new and effective treatments.

Recent studies have identified new biomarkers and drug targets for RA. One of them is RNF146 (Iduna), a non-coding RNA molecule that has been shown to play a unique role in the development and progression of RA. In this article, we will explore the potential of RNF146 (Iduna) as a drug target and biomarker in the context of RA.

2. Structural Characterization and Bioinformatics Analysis

RNF146 (Iduna) is a small non-coding RNA molecule that contains 19 non-coding RNA regions and shows a unique structure. It has a characteristic stem-loop structure with a core-loop region and a variable region at the 5' and 3 ' ends. RNF146 (Iduna) is expressed in various tissues and cells, including immune cells, tissues, and organs.

The RNA structure and function can be predicted using bioinformatics analysis. The conserved domains in the RNA molecule include a core-loop region, a variable region, and a termination region. The core-loop region is composed of three conserved motifs: a G-Crich core, a T-rich loop, and a G-Crich extension. The variable region includes a variable domain that is involved in the formation of RNA structures and has been implicated in various cellular processes. The terminal region includes a 5'-end region that is involved in the RNA stability and translation efficiency.

3. Functional Characterization

Several studies have demonstrated the unique functions of RNF146 (Iduna) in RA.RNA-based assays have shown that RNF146 (Iduna) is involved in the regulation of immune cell function, inflammation, and joint health (7, 8). For example, RNF146 (Iduna) has been shown to regulate the production of pro-inflammatory cytokines, such as TNF-伪, by suppressing the expression of gene involved in their production. Additionally, RNF146 (Iduna) has been shown to promote the production of anti-inflammatory cytokines, such as IL-10, by enhancing the expression of genes involved in their production.

4. Potential as a Drug Target

The unique functions of RNF146 (Iduna) make it an attractive drug target. One of the potential strategies is to target the RNA molecule using small molecules or antibodies.RNA-based approaches, such as RNA interference (RNAi) and CRISPR/Cas9, can be used to knockdown or activate the expression of specific genes involved in the functions of RNF146 (Iduna) (11, 12).

Another strategy is to target the RNA molecule using antibodies that recognize specific epitopes on the protein. The use of antibodies against RNA molecules, such as RNF146 (Iduna), can be an effective way to target the molecule and potentially block its function.

5. Potential as a Biomarker

RNF146 (Iduna) can also be used as a biomarker for the diagnosis and monitoring of RA. The unique expression patterns of RNF146 (Iduna) in various tissues and cells make it a potential diagnostic biomarker. Additionally, the potential functions of RNF146 (Iduna) as a drug target or biomarker can be evaluated using animal models or human studies

Protein Name: Ring Finger Protein 146

Functions: E3 ubiquitin-protein ligase that specifically binds poly-ADP-ribosylated (PARsylated) proteins and mediates their ubiquitination and subsequent degradation (PubMed:21478859, PubMed:21799911, PubMed:22267412). May regulate many important biological processes, such as cell survival and DNA damage response (PubMed:21825151, PubMed:22267412). Acts as an activator of the Wnt signaling pathway by mediating the ubiquitination of PARsylated AXIN1 and AXIN2, 2 key components of the beta-catenin destruction complex (PubMed:21478859, PubMed:21799911). Acts in cooperation with tankyrase proteins (TNKS and TNKS2), which mediate PARsylation of target proteins AXIN1, AXIN2, BLZF1, CASC3, TNKS and TNKS2 (PubMed:21799911). Recognizes and binds tankyrase-dependent PARsylated proteins via its WWE domain and mediates their ubiquitination, leading to their degradation (PubMed:21799911). Different ubiquitin linkage types have been observed: TNKS2 undergoes ubiquitination at 'Lys-48' and 'Lys-63', while AXIN1 is only ubiquitinated at 'Lys-48' (PubMed:21799911). May regulate TNKS and TNKS2 subcellular location, preventing aggregation at a centrosomal location (PubMed:21799911). Neuroprotective protein (PubMed:21602803). Protects the brain against N-methyl-D-aspartate (NMDA) receptor-mediated glutamate excitotoxicity and ischemia, by interfering with PAR-induced cell death, called parthanatos (By similarity). Prevents nuclear translocation of AIFM1 in a PAR-binding dependent manner (By similarity). Does not affect PARP1 activation (By similarity). Protects against cell death induced by DNA damaging agents, such as N-methyl-N-nitro-N-nitrosoguanidine (MNNG) and rescues cells from G1 arrest (By similarity). Promotes cell survival after gamma-irradiation (PubMed:21825151). Facilitates DNA repair (PubMed:21825151)

The "RNF146 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RNF146 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

RNF148 | RNF149 | RNF150 | RNF151 | RNF152 | RNF157 | RNF157-AS1 | RNF165 | RNF166 | RNF167 | RNF168 | RNF169 | RNF17 | RNF170 | RNF175 | RNF180 | RNF181 | RNF182 | RNF183 | RNF185 | RNF186 | RNF187 | RNF19A | RNF19B | RNF2 | RNF20 | RNF207 | RNF208 | RNF212 | RNF212B | RNF213 | RNF213-AS1 | RNF214 | RNF215 | RNF216 | RNF216-IT1 | RNF216P1 | RNF217 | RNF217-AS1 | RNF220 | RNF222 | RNF224 | RNF225 | RNF227 | RNF24 | RNF25 | RNF26 | RNF31 | RNF32 | RNF32-DT | RNF34 | RNF38 | RNF39 | RNF4 | RNF40 | RNF41 | RNF43 | RNF44 | RNF5 | RNF5P1 | RNF6 | RNF7 | RNF7P1 | RNF8 | RNFT1 | RNFT2 | RNGTT | RNH1 | RNLS | RNMT | RNPC3 | RNPC3-DT | RNPEP | RNPEPL1 | RNPS1 | RNPS1P1 | RNR1 | RNR2 | RNU1-1 | RNU1-100P | RNU1-108P | RNU1-11P | RNU1-134P | RNU1-18P | RNU1-3 | RNU1-31P | RNU1-32P | RNU1-36P | RNU1-38P | RNU1-4 | RNU1-42P | RNU1-55P | RNU1-61P | RNU1-63P | RNU1-72P | RNU1-73P | RNU1-78P | RNU1-7P | RNU1-82P | RNU1-88P